Abstract: A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.

Abstract: Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage.

Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

Abstract: Provided herein are pharmaceutical compositions and kits useful for sensitizing a microorganism or a population of microorganisms to a quinolone antibiotic. In a particular aspect, a carbon source and an electron acceptor can sensitize an antibiotic persistent microorganism to treatment with a fluoroquinolone antibiotic. Methods for sensitizing a microorganism to a quinolone antibiotic, reducing the density-dependent persistence (DDP) of an antibiotic resistant microorganism, and reducing the number of persistent cells in a population are also provided. Theses compositions and methods are useful in treating infections resulting from high-density bacterial cultures, such as pneumonia, genitourinary infections, biofilms, prosthetic graft infections, sepsis, and endovascular infections.

Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.

Abstract: A statin-encapsulated nanoparticle contains a bioabsorbable polymer and statin encapsulated in the nanoparticle. Suitable bioabsorbable polymers include a polylactic acid (PLA) polymer or a polylactic acid-glycolic acid (PLGA) copolymer. The statin-encapsulated nanoparticle can be used to enhance the function of a stem cell. The stem cell can be a stem cell for treating an inflammatory disease.

Abstract: Objects of the present invention are to provide a preparation method which makes it possible to obtain porous microcarriers having unique properties and a unique particle size distribution and to provide porous gelatin microcarriers having excellent cell growth properties. According to the present invention, there are provided a method for preparing porous recombinant gelatin microcarriers that includes an emulsification step in which an emulsifier having a specific HLB value is used in a specific amount, and provided porous gelatin microcarriers having specific voids.

Abstract: The present application provides bifunctional compounds of Formula (I): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to said surface through a linker comprising a thioether.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.

Abstract: The invention relates to conjugates comprising amatoxins and antibodies, in particular amatoxins linked to antibodies comprising specific cysteine residues.

Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.

Abstract: The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion of the coding sequence is not wild type. The present invention further relates to viral particles comprising a recombinant genome comprising the polynucleotide of the invention, compositions comprising the polynucleotides or viral particles, and methods and uses of the polynucleotides, viral particles or compositions.

Abstract: The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.

Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Abstract: The present invention provides a method for the commercial presentation of a solution of gadolinium-DOTA that provides certain advantages over the known methods.

Abstract: A contrast composition for photoacoustic imaging includes a photoacoustic contrast agent and a gelling agent.

Abstract: Example substances and methods relating to contrast agents are provided. An example method includes combining a surface active protein, a stabilizer, and a dispersion media to form a solution. The example method may further include aerating the solution in a gas to form a contrast agent comprising at least one microbubble formed from an interaction between the surface active protein and the stabilizer. A diameter of the at least one microbubble may be proportional to a pressure of an external environment of the contrast agent, such that measurement of the diameter may allow for measurement of the pressure.

Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.

Abstract: Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

Abstract: A disinfecting device for use in disinfecting a container, wherein the device includes a light source configured to emit an antimicrobial wavelength on one or more surfaces of the container as the container passes through the disinfecting device.

Abstract: A germicidal motion-detecting lighting system includes a plurality of lighting units configured to electrically connect to one another. Each modular lighting unit has an enclosure, having an enclosure, a light emission window positioned within a first cavity of the enclosure, and a plurality of light emitting diodes positioned within the first enclosure, at least one motion sensor that protrudes through a second cavity of the enclosure, and a processor positioned within the enclosure that detects motion of a user based on data received from the at least one motion sensor and generates an activation command to emit visible light based on the motion of the user. The plurality of light emitting diodes receives the command and emits visible light based on the command. One of the modular lighting units further includes an additional enclosure with a third cavity in which an additional light emission window is positioned to emit ultraviolet light via an additional plurality of light emitting diodes.

Abstract: A device for disinfecting a portable object comprising: a housing comprising an outlet, and wherein the housing encloses a central cavity; a first panel located on an upper surface of the housing, the first panel configured to move between an open and a closed position, wherein in a closed position, the panel is configured to receive the portable object, and wherein in an open position, the object is configured to be moved into the cavity; a first platform configured inside the cavity, the first platform configured to move the object between a first position and a second position inside the cavity; and a plurality of ultraviolet (UV) lights positioned over an upper surface of the first platform and along inner sidewalls of the housing cavity, wherein the UV lights are configured to emit UV light of a predetermined wavelength to disinfect the object. The disinfected object is transferred to a conveyor which moves the object towards the outlet.

Abstract: The present invention extends to methods, apparatus, and systems for disinfecting articles with ozone. Aspects of the invention use increased concentrations ozone in sealed, confined volumes, such as, for example, carts, lockers, cabinets, etc. to disinfect or sterilize medical articles. A medical article is placed in a confined volume. The confined volume is sealed so that the atmosphere inside the sealed, confined volume is isolated from the external atmosphere. The concentration of ozone in the sealed, confined volume is rapidly increased to a threshold concentration. At the threshold ozone concentration, the medical article can be disinfection or sterilized in a reduce amount of time. When disinfection or sterilization is complete, the concentration of ozone in the sealed, confined volume is rapidly reduced to a safe level. The sealed, confined volume is unsealed. The disinfected or sterilized medical article can be removed from the confined volume.

Abstract: The present disclosure is generally related to devices, methods and systems for cleaning, disinfecting and/or sterilizing a medical device, medical hoses and tubes and accessories thereof with ozone gas, in particular the disclosure relates to devices, methods and systems with multiple receptacles for providing closed-loop fluid pathways to distribute ozone gas to inner passageways and the outer compartments of medical devices. The devices in accordance with an embodiment of the disclosure have two or more receptacles for distributing ozone gas, a gas-tight compartment, an ozone operating system, and one or more connector units configured to fluidly migrate ozone in closed-loop treatment systems.

Abstract: A sanitizer dispensing glove and a method of sanitizing an object using the glove. The sanitizer dispensing glove has a spray mechanism which is located on the palmar surface of a glove or mitt which is able to be operated to spray a sanitizer solution onto an object by a flexing or closing of a hand, finger, or other appendage wearing the glove without making contact with the object.

Abstract: An air treatment article is provided, comprising: a semipermeable barrier and a plurality of multi-staged non-film forming polymer abatement particles having a core polymer and at least one shell polymer; wherein the core polymer accounts for 1 to 25 wt % of the weight of the non-film forming polymer abatement particles; wherein the semipermeable barrier is disposed between an air atmosphere and the non-film forming polymer abatement particles; wherein the semipermeable barrier impedes passage therethrough by the non-film forming polymer abatement particles; wherein the semipermeable barrier permits passage therethrough by a for-treatment air containing a contaminant such that the for-treatment air can make contact with the non-film forming polymer abatement particles; wherein the non-film forming polymer abatement particles have an affinity for the contaminant.

Abstract: A plug-in fragrance dispenser contains: a body, an electric plug, a heating element, a heat transfer plate, and a holder. The electric plug is electrically connected with a power source, and the body is coupled with the electric plug and includes a first orifice, a first connection part, and a second connection part. The first connection part is connected with the second connection part, the first connection part has an accommodation lid and a surround sleeve, and the surround sleeve has the first orifice defined on a top thereof. The accommodation lid has a second orifice in which the electric plug is accommodated, the second connection part has a support seat and a first cap formed on an upper end of the support seat and connecting with a bottom of the surround sleeve, wherein the support seat is housed in the accommodation lid.

Abstract: A treated vapor permeable microporous membrane includes: a microporous membrane having a first side and a second side opposite the first side. The membrane includes a thermoplastic organic polymer having a polyolefin. The membrane defines a network of interconnecting pores communicating substantially throughout the membrane. The treated membrane further includes finely divided, particulate filler distributed throughout the membrane and a first hydrophobic/oleophobic material over at least a portion of the first side. A method of preparing the treated vapor permeable microporous membrane is also disclosed.

Abstract: Provided are an aroma diffusing apparatus and an oil supply method. The aroma diffusing apparatus includes a main body and an oil storage tube. The main body is provided with a liquid storage chamber which is configured to store a liquid. The oil storage tube is configured to store an essential oil. When the aroma diffusing apparatus works, a bottom portion of the oil storage tube may be in fluidic communication with the liquid storage chamber thus allowing the essential oil in the oil storage tube to flow from the bottom of the oil storage tube into the liquid storage chamber as the liquid in the liquid storage chamber is being consumed.

Abstract: Disclosed herein is a sterilization and drying device. The sterilization and drying device includes: a body configured to be coupled to the inside of a sterilization target, and to suck and discharge internal air of the sterilization target; a silicon carbide honeycomb heater installed inside the body, and configured to sterilize, purify, dry, and heat the sucked air and discharge the sterilized, purified, dried, and heated air; an air circulation fan installed behind the silicon carbide honeycomb heater, and configured such that the internal air of the sterilization target is sucked, passed through the silicon carbide honeycomb heater, and then discharged; and a battery installed on one side of the air circulation fan, and configured to supply power to the silicon carbide honeycomb heater and the air circulation fan.

Abstract: Provided is an air sterilizer for filtering and discharging harmful components from inflowing air, comprising: a body having an air inlet part, through which outside air is introduced, and an air outlet part, through which the air filtered inside is discharged; a primary filtering part detachably provided in the body and filtering contaminant particles from the inflowing and moving air; an air intake fan for allowing the air to inflow through the air inlet part; a secondary electrostatic filter part for sterilizing harmful components from the air, which has been filtered through the primary filtering part, by applying continuous and repetitive damage to the harmful components; and an ion-generating part for supplying anions to the air, from which the harmful components have been filtered through the secondary electrostatic filter part, so as to allow the air to be discharged to the outside.

Abstract: An air purifier includes a upper cover, having at least one grid column on front terminal of the upper cover; a bottom cover, having at least one grid column on front terminal of the bottom cover; and two groups of ultraviolet light emitting diodes (LEDs), respectively having a heat sink and a ultraviolet light emitting diode (LED), wherein the ultraviolet LED is mounted on the heat sink, and a wavelength range of the ultraviolet LED is between 100 nm and 480 nm; wherein the grid column on front terminal of the upper cover is combined with the grid column on front terminal of the bottom cover to form a column hole through which an air flows out.

Abstract: A system for disinfecting a fluid containing contaminants (chemical and biological) includes a plurality of photocatalytic particles secured to a substrate which contacts the fluid to be disinfected. An agitator for imparting translation and/or vibrational movement is in operational communication with the substrate to increase the contact of photocatalytic particles with contaminants in the fluid. The system can include a source of photons having a wavelength corresponding to band gap energy of the photocatalytic particles to illuminate the substrate. Although the invention can be used to disinfect air in air supply registers of a heating, ventilating and air conditioning system, or in air ducts, the disinfection of any fluid (including water) is contemplated.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection.

Abstract: Embodiments of this technology may include an apparatus for drying tissue. The apparatus may include human donor tissue placed in contact with and between at least two layers of backing material. This tissue and backing layer may then be restrained by two plates. This tissue may be amniotic tissue. The backing layer may include woven or nonwoven material. This backing layer may be wetted with a saline solution. At least one of the plates of the tissue drying apparatus may be perforated. The tissue assembly along with the plates may then be placed inside a chamber configured to receive the plates and tissue assembly. The chamber may be configured so that gas can be forced into the chamber with the gas flow going around the plates and the tissue assembly.

Abstract: Provided are an alloy member which is usable in organisms, makes use of features of bio-affinity and biodegradability of magnesium, and is able to realize required duration of biodegradability, and a production method therefor. According to the present invention, the alloy member usable in organisms includes a base body that contains a magnesium alloy, a first protective layer that contains an oxide derived from a component of the base body or a complex of an oxide and a hydroxide derived from a component of the base body, and a second protective layer that contains a hydroxide derived from a component of the base body.

Abstract: A coating for a metal surface, the coating including poly(ethylene glycol) disposed on and covalently bonded directly to at least a portion of the metal surface, and a functional group grafted to at least a portion of the poly(ethylene glycol). The functional group is one of a bioactive functional group and an antimicrobial functional group.

Abstract: Tissue repair and restoration can be performed using an elastic material formed from tropoelastin. The elastic material can be formed by providing a solution of tropoelastin monomers, applying the solution to a surface, and heating the solution on the surface in absence of a cross-linking agent to enable the tropoelastin monomers to bind to each other to form an elastic material that does not dissociate into tropoelastin monomers when the elastic material is contacted with an aqueous solution.

Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally methods and related kits for the repair of articular tissue using the collagen material are provided.

Abstract: Provided herein are hip implant devices and related surgical methods. The hip implants and methods can optionally be used in patients of Asian descent.

Abstract: This disclosure provides a method for reducing or preventing the formation and/or accumulation of drusen in an eye of a mammalian subject in need thereof, the method comprising implanting one or more microporous devices into the eye, each device having a device body and an outer surface, wherein the microporous device is formed of a biocompatible elastomeric material and comprises a plurality of interconnected pores throughout the device body.

Abstract: A chronically implanted medical device is disclosed that has an outermost layer formed from a conjugate of a polymer with lipoic acid, the conjugate having free 1,2-dithiolane groups. It is contemplated that this layer scavenges reactive oxygen species, i.e. acts as an antioxidant, and thus reduces inflammation and other adverse effects around the implant itself.

Abstract: A length extensible implantable device includes a porous member and a longitudinal constraining member. The longitudinal constraining member can constrain at least a portion, up to the entire length of, the porous member in the longitudinal direction. The length of the longitudinally constrained portion can be expanded by applying force to the porous member. The porous member may be a porous tubular member.

Abstract: A wound treatment appliance is provided for treating all or a portion of a wound. In some embodiments, the appliance comprises a cover or a flexible overlay that covers all or a portion of the wound for purposes of applying a reduced pressure to the covered portion of the wound. In other embodiments, the wound treatment appliance also includes a vacuum system to supply reduced pressure to the site of the wound in the volume under the cover or in the area under the flexible overlay. Methods are provided for using various embodiments of the invention.

Abstract: This document provides systems and methods that can improve the efficacy of tube and needle thoracostomy. For example, this document provides devices and methods for confirming the proper placement of a chest tube or needle within the pleural space to relieve a pneumothorax or tension pneumothoax.